Comparative Pharmacology
Head-to-head clinical analysis: HYDROCHLOROTHIAZIDE versus HYDROFLUMETHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCHLOROTHIAZIDE versus HYDROFLUMETHIAZIDE.
HYDROCHLOROTHIAZIDE vs HYDROFLUMETHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the kidney, reducing reabsorption of sodium and chloride, leading to increased excretion of water and electrolytes.
Hydroflumethiazide is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption and promoting diuresis. It also causes vasodilation by reducing peripheral vascular resistance.
Oral: 25-100 mg daily in 1-2 divided doses. Maximum dose 200 mg/day.
Oral: 25-50 mg once daily; may increase to 100 mg/day in divided doses if needed.
MODERATE Risk
MODERATE Risk
Clinical Note
moderateHydrochlorothiazide + Digoxin
"The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Digoxin."
Clinical Note
moderateHydroflumethiazide + Digoxin
"The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Digoxin."
Clinical Note
moderateHydrochlorothiazide + Digitoxin
"The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Digitoxin."
Clinical Note
moderateTerminal elimination half-life is 5.6–14.8 hours (mean ~9 hours). In patients with renal impairment (CrCl <30 mL/min), half-life is prolonged up to 24–48 hours, necessitating dose adjustment.
Terminal elimination half-life of 6-9 hours in patients with normal renal function; clinically, this supports once-daily dosing in hypertension but may require twice-daily dosing in some patients with impaired renal function
Primarily renal (≥95%) via glomerular filtration and tubular secretion, with approximately 60% of the dose excreted unchanged in urine. Minor biliary/fecal excretion accounts for <5%.
Primarily renal (approximately 85% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal elimination (<10%)
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic
Hydroflumethiazide + Digitoxin
"The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Digitoxin."